Brindley PJ, Bachini M, Ilyas SI, et al. Cholangiocarcinoma. Nat Rev Dis Primers. 2021;7(1):65. https://doi.org/10.1038/s41572-021-00300-2.

Article  PubMed  PubMed Central  Google Scholar 

Rodrigues PM, Olaizola P, Paiva NA, et al. Pathogenesis of cholangiocarcinoma. Annu Rev Pathol. 2021;16:433–63. https://doi.org/10.1146/annurev-pathol-030220-020455.

Article  CAS  PubMed  Google Scholar 

Guedj N. Pathology of cholangiocarcinomas. Curr Oncol. 2022;30(1):370–80. https://doi.org/10.3390/curroncol30010030.

Article  PubMed  PubMed Central  Google Scholar 

Khan SA, Tavolari S, Brandi G. Cholangiocarcinoma: epidemiology and risk factors. Liver Int. 2019;39(Suppl 1):19–31. https://doi.org/10.1111/liv.14095.

Article  PubMed  Google Scholar 

Donato F, Gelatti U, Tagger A, et al. Intrahepatic cholangiocarcinoma and hepatitis C and B virus infection, alcohol intake, and hepatolithiasis: a case-control study in Italy. Cancer Causes Control. 2001;12(10):959–64. https://doi.org/10.1023/a:1013747228572.

Article  CAS  PubMed  Google Scholar 

Welzel TM, Graubard BI, El-Serag HB, et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clin Gastroenterol Hepatol. 2007;5(10):1221–8. https://doi.org/10.1016/j.cgh.2007.05.020.

Article  PubMed  PubMed Central  Google Scholar 

Prueksapanich P, Piyachaturawat P, Aumpansub P, et al. Liver fluke-associated biliary tract cancer. Gut Liver. 2018;12(3):236–45. https://doi.org/10.5009/gnl17102.

Article  CAS  PubMed  Google Scholar 

Banales JM, Cardinale V, Macias RIR, et al. Cholangiocarcinoma: state-of-the-art knowledge and challenges. Liver Int. 2019;39(Suppl 1):5–6. https://doi.org/10.1111/liv.14101.

Article  PubMed  Google Scholar 

Scott A, Wong P, Melstrom LG. Surgery and hepatic artery infusion therapy for intrahepatic cholangiocarcinoma. Surgery. 2023;174(1):113–5. https://doi.org/10.1016/j.surg.2023.01.019.

Article  PubMed  Google Scholar 

Cillo U, Fondevila C, Donadon M, et al. Surgery for cholangiocarcinoma. Liver Int. 2019;39(Suppl 1(Suppl Suppl 1)):143–55. https://doi.org/10.1111/liv.14089.

Article  PubMed  PubMed Central  Google Scholar 

Ilyas SI, Khan SA, Hallemeier CL, Kelley RK, Gores GJ. Cholangiocarcinoma—evolving concepts and therapeutic strategies. Nat Rev Clin Oncol. 2018;15(2):95–111. https://doi.org/10.1038/nrclinonc.2017.157.

Article  CAS  PubMed  Google Scholar 

Moris D, Palta M, Kim C, et al. Advances in the treatment of intrahepatic cholangiocarcinoma: an overview of the current and future therapeutic landscape for clinicians. CA Cancer J Clin. 2023;73(2):198–222. https://doi.org/10.3322/caac.21759.

Article  PubMed  Google Scholar 

Merath K, Tiwari A, Parikh AA, Pawlik TM. Molecular targeted and systemic therapy for intrahepatic cholangiocarcinoma: a multi-disciplinary approach. Future Oncol. 2023;19(39):2607–21. https://doi.org/10.2217/fon-2023-0098.

Article  CAS  PubMed  Google Scholar 

Li Y, Yu J, Zhang Y, et al. Advances in targeted therapy of cholangiocarcinoma. Ann Med. 2024;56(1):2310196. https://doi.org/10.1080/07853890.2024.2310196.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Abou-Alfa GK, Macarulla T, Javle MM, et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21(6):796–807. https://doi.org/10.1016/s1470-2045(20)30157-1.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hyman DM, Puzanov I, Subbiah V, et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med. 2015;373(8):726–36. https://doi.org/10.1056/NEJMoa1502309.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Goyal L, Kongpetch S, Crolley VE, Bridgewater J. Targeting FGFR inhibition in cholangiocarcinoma. Cancer Treat Rev. 2021;95: 102170. https://doi.org/10.1016/j.ctrv.2021.102170.

Article  CAS  PubMed  Google Scholar 

Goyal L, Meric-Bernstam F, Hollebecque A, et al. Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma. N Engl J Med. 2023;388(3):228–39. https://doi.org/10.1056/NEJMoa2206834.

Article  CAS  PubMed  Google Scholar 

Huang SB, Zheng CX. Gene alterations and epigenetic changes in intrahepatic cholangiocarcinoma. Expert Rev Anticancer Ther. 2017;17(1):89–96. https://doi.org/10.1080/14737140.2017.1266261.

Article  CAS  PubMed  Google Scholar 

Viereckl MJ, Krutsinger K, Apawu A, et al. Cannabidiol and cannabigerol inhibit cholangiocarcinoma growth in vitro via divergent cell death pathways. Biomolecules. 2022;12(6):854. https://doi.org/10.3390/biom12060854.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Huang P, Zhang PF, Li Q. Causal relationship between cannabis use and cancer: a genetically informed perspective. J Cancer Res Clin Oncol. 2023;149(11):8631–8. https://doi.org/10.1007/s00432-023-04807-x.

Article  PubMed  Google Scholar 

Oliveira G, Wu CJ. Dynamics and specificities of T cells in cancer immunotherapy. Nat Rev Cancer. 2023;23(5):295–316. https://doi.org/10.1038/s41568-023-00560-y.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Du J, Lv X, Zhang Z, Huang Z, Zhang E. Revisiting targeted therapy and immunotherapy for advanced cholangiocarcinoma. Front Immunol. 2023;14:1142690. https://doi.org/10.3389/fimmu.2023.1142690.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang S, Zou R, Dai Y, et al. Tumor immune microenvironment and the current immunotherapy of cholangiocarcinoma (review). Int J Oncol. 2023;63(6):1–23. https://doi.org/10.3892/ijo.2023.5585.

Article  CAS  Google Scholar 

Lu X, Green BL, Xie C, Liu C, Chen X. Preclinical and clinical studies of immunotherapy for the treatment of cholangiocarcinoma. JHEP Rep. 2023;5(7): 100723. https://doi.org/10.1016/j.jhepr.2023.100723.

Article  PubMed  PubMed Central  Google Scholar 

Liu J, Shu J. Immunotherapy and targeted therapy for cholangiocarcinoma: artificial intelligence research in imaging. Crit Rev Oncol Hematol. 2024;194: 104235. https://doi.org/10.1016/j.critrevonc.2023.104235.

Article  PubMed  Google Scholar 

Zhao LM, Shi AD, Yang Y, et al. Advances in molecular and cell therapy for immunotherapy of cholangiocarcinoma. Front Oncol. 2023;13:1140103. https://doi.org/10.3389/fonc.2023.1140103.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ueno M, Ikeda M, Morizane C, et al. Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study. Lancet Gastroenterol Hepatol. 2019;4(8):611–21. https://doi.org/10.1016/s2468-1253(19)30086-x.

Article  PubMed